BridgeBio Oncology Therapeutics, Inc.

Bridgebio Oncology Therapeutics, Inc.

Biotechnology • Healthcare • South San Francisco, CA, United States • BBOT (NGM)

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I clinical trial for treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS pancreatic ductal adenocarcinoma (PDAC), KRAS mutant colorectal cancer (CRC), and KRAS mutant NSCLC. It is also developing BBO-11818, an orally bioavailable pan KRAS on/off inhibitor that is in Phase I clinical trial to treat patients with KRASG12D and KRASG12V mutant NSCLC, PDAC, and CRC. The company was founded in 2016 is headquartered in South San Francisco, California.

650 405 4770 256 E. Grand Avenue, South San Francisco, CA 94080, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Assessing BridgeBio Oncology Therapeutics (BBOT) Valuation After Recent Share Price Pullback - Yahoo Finance
Yahoo Finance • Dec 15
BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least - Seeking Alpha
Seeking Alpha • Dec 12
BridgeBio Oncology Therapeutics Rings the Closing Bell - Nasdaq
Nasdaq • Oct 3
BridgeBio oncology spinout to go public in blank-check merger - BioPharma Dive
BioPharma Dive • Feb 28
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines - Business Wire
Business Wire • Feb 28

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has BridgeBio Oncology Therapeutics, Inc. had layoffs?
No layoff events have been recorded for BridgeBio Oncology Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does BridgeBio Oncology Therapeutics, Inc. have?
BridgeBio Oncology Therapeutics, Inc. has approximately 81 employees.
What industry is BridgeBio Oncology Therapeutics, Inc. in?
BridgeBio Oncology Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is BridgeBio Oncology Therapeutics, Inc. a publicly traded company?
Yes, BridgeBio Oncology Therapeutics, Inc. is publicly traded under the ticker symbol BBOT on the NGM. The company has a market capitalization of approximately $0.99 billion.
Where is BridgeBio Oncology Therapeutics, Inc. headquartered?
BridgeBio Oncology Therapeutics, Inc. is headquartered in South San Francisco, CA, United States at 256 E. Grand Avenue, South San Francisco, CA 94080, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.